
SMS Pharmaceuticals Q1 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
No
Order
N/A
Capex
No
0 of 4 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- SMS Pharmaceuticals reported a strong Q1 FY24 with 110% year-on-year revenue growth, reaching INR 135 crores.
- The company expects 15%-20% revenue and profit growth for FY24 compared to FY23.
- Growth is driven by a robust API business, especially high-volume products like Ibuprofen, with capacity expandable from 700 MT to 1,200 MT/month once 80-85% utilization is achieved.
- The ARV segment is recovering with expected sustainable volumes in next few quarters.
- Diversification into anti-diabetic, anti-migraine, anti-ulcer, and anti-ED segments supports stability and growth.
- Focus on expanding regulated export markets where profitability is higher.
- Long-term plan includes making Ibuprofen one of the largest globally.
- Vertical integration for selected high-volume products is underway to improve margins.
- No major capex planned currently; consolidation and backward integration are priorities.
- New product launches and geographical expansion efforts are ongoing, with impact expected near fiscal year-end.
See what SMS Pharmaceuticals management said on margin guidance — free account, 30 seconds.
Fundraise plans
No- There are no immediate major capex plans or greenfield projects planned at this time.
- The company intends to consolidate and focus on backward integration of critical, high-volume products.
- No mention was made of any new fundraising through either debt or equity in the recent call.
- Current capacity utilization is around 50%-55%, and expansions or major investments will be considered only after optimizing existing capacity.
- Management did not indicate any plans for raising funds via debt or equity during the discussed period.
See what SMS Pharmaceuticals management said on order book — free account, 30 seconds.
Capex plans
No- No immediate major capex or greenfield projects planned at present.
- Focus is on consolidating current operations and pursuing backward integration for critical, high-volume APIs.
- Plans for vertical integration are already underway for top five to six key products.
- Expansion of capacity, such as for Ibuprofen from current 700 metric tons to 1,200 metric tons per month, will only occur after reaching about 80-85% utilization of existing capacity.
- The company aims to improve operational efficiency and margins through R&D focused on cost and process improvements as well as backward integration.
- Any major capex expansions are deferred until current capacities are optimally utilized.
- The approach is cautious with emphasis on sustainable growth and maximizing in-house manufacturing capabilities rather than immediate large-scale investment.
Track SMS Pharmaceuticals — get its next earnings analysis in your feed
How does SMS Pharmaceuticals rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does SMS Pharmaceuticals rank in Pharmaceuticals & Biotechnology?
Compare SMS Pharmaceuticals against every Pharmaceuticals & Biotechnology company (Q1 FY24) on revenue, margins and earnings-call signals.
Continue your research
What SMS Pharmaceuticals's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem